Clinical-Stage Pharmaceutical Company Advancing Phase IIa Parkinson’s Trial
Dual-Path Strategy Targets Neuroinflammation While Expanding Nugevia™ Longevity Brand
NEW YORK, NY - February 12, 2026 (NEWMEDIAWIRE) - B2i Digital, Inc., a capital markets positioning and investor connectivity platform focused on growth-stage public companies, today announced that Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has been selected as a B2i Digital Featured Company.
Jupiter Neurosciences is advancing a therapeutic pipeline targeting neuroinflammation and central nervous system (CNS) disorders, led by an FDA-cleared Phase IIa clinical trial in Parkinson’s disease. The company is also exploring additional indications including Alzheimer’s disease, Friedreich’s Ataxia, Mucopolysaccharidoses Type I, and MELAS, supported by research collaborations with Harvard University, Georgetown University, MIT’s Picower Institute, and the University of Miami.
Alongside its clinical program, Jupiter is expanding Nugevia™, a consumer longevity brand powered by its proprietary JOTROL™ enhanced resveratrol formulation. This dual-path strategy combines clinical development with emerging commercial revenue pathways, creating a differentiated operating model as key milestones advance.
“Jupiter Neurosciences offers investors a differentiated opportunity within the CNS sector,” said David Shapiro, Chief Executive Officer of B2i Digital. “With a Phase IIa Parkinson’s trial underway and a consumer longevity platform already in market, the company is advancing its pipeline while building potential revenue streams. We look forward to expanding their visibility across our investor network.”
“We believe we are entering an important inflection point,” said Christer Rosén, Founder, Chairman and CEO of Jupiter Neurosciences. “As our Parkinson’s program progresses and Nugevia continues to scale, partnering with B2i Digital strengthens our ability to communicate our story to the broader capital markets.”
To learn more about Jupiter Neurosciences, visit www.jupiterneurosciences.com.
For investor inquiries, contact IR@jupiterneurosciences.com.
About B2i Digital, Inc.
B2i Digital, Inc. is a capital markets positioning and investor connectivity platform serving growth-stage public companies. Through its Featured Conference, Featured Company, and Featured Expert programs, B2i Digital helps management teams sharpen their capital markets narrative and engage directly with active investors across the investor conference ecosystem.
Acting as The Capital Markets Matchmaker℠, B2i Digital leverages a proprietary network of more than 1.5 million capital markets participants and a curated email distribution of more than 100,000 investors and industry professionals to move companies from marketing to meaningful investor meetings. Its approach, captured in the mantra From Marketing to Meetings℠, reflects a focus on measurable investor engagement. Founded in 2021 by former Maxim Group investment banker and Chief Marketing Officer David Shapiro, B2i Digital is headquartered in New York City.
B2i Digital Contact Information:
David Shapiro
Chief Executive Officer
B2i Digital, Inc.
https://b2idigital.com
212.579.4844 Office
david@b2idigital.com
https://www.linkedin.com/in/davidshapironyc
https://www.linkedin.com/company/b2i-digital
https://x.com/b2idigital
https://www.facebook.com/b2idigital
https://www.instagram.com/b2i_digital
https://www.youtube.com/@b2idigital
https://stocktwits.com/B2iDigital
https://www.reddit.com/user/b2idigital/
https://www.pinterest.com/b2idigital/
https://www.tiktok.com/@b2idigital
https://bsky.app/profile/b2idigital.bsky.social
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases while expanding into the consumer longevity market with its Nugevia™ product line. Both initiatives are powered by JOTROL™, Jupiter’s proprietary enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia™ brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s pipeline is focused broadly on CNS disorders and currently includes a Phase IIa clinical trial in Parkinson’s disease, with additional exploration in Alzheimer’s disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS.
More information may be found at www.jupiterneurosciences.com.
Contact Information:
Jupiter Neurosciences, Inc.
IR@jupiterneurosciences.com
https://www.linkedin.com/company/jupiterneurosciences/
https://x.com/jupiterneuro
View the original release on www.newmediawire.com
